Countries / Uganda
UG · NDA
Uganda
- Authority
- National Drug Authority (NDA)
- Legal basis
- Not recorded
- Address
- Not recorded
- Website
- https://www.nda.or.ug
- Notice channel
- https://www.nda.or.ug/circulars-2/Circulars are Uganda's real channel. The legacy recalls page has been dead since 2018.
- Coverage
- PartialThe most recent run read nothing from this channel, and the 17 before it. The authority's server refused the request or did not answer, so it was not read. It last yielded records on 14 September 2026. Anything published since is not on this page.
- Cadence
- DailyLast read 3 October 2026.
- On the register
- 12 recorded actions
- Last verified
- 19 August 2026
Authority Channel
A named officer of NDA can put a Uganda alert on the register directly, with no review step of ours. Those records carry Tier 0 — entered and published by the issuing regulator, which is the one rank we cannot create for ourselves.
Nothing on this page carries Tier 0 today because no NDA officer holds a credential yet. We issue one after confirming, out of band, that a person speaks for their authority — write to notices@drugeyeafrica.org. Notices can also be sent by email, by export, or from an existing system: how to send them.
What we monitor, and what we cannot. PDF-only publication; requires OCR before dates and batches exist. Cadence: Daily. Last checked 19 August 2026.
| Reference | Date | Country | Product | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-UG-2026-18763434 | 03 Mar 2026 | UG | Unauthorized sale of public family planning commodities in the private sector | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2025-48246675 | 04 Dec 2025 | UG | Paracetamol-containing oral solid dosage forms | none published | Scheduling change | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-49858519 | 11 Sept 2024 | UG | Circular on Unaunthorised Medical Devices on the Ugandan Market | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-54413197 | 20 Feb 2024 | UG | Ketoconazole oral tablets | none published | Deregistration | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2023-17500876 | 18 Aug 2023 | UG | Adulterated L-power coffee supplied by Liven Global SDN. BHD – Malaysia | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-85899679 | 13 Oct 2022 | UG | Unauthorized Chinese Pill Tablets on the Market | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-27953969 | 10 Oct 2022 | UG | WHO Global alert on substandard (contaminated) pediatric cough syrups identified in Gambia – West Africa | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-47522751 | 25 Jul 2022 | UG | Ban on the use Chloroform (Trichloromethane) in Pharmaceutical preparations | none published | Ban | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-36916109 | 31 Oct 2019 | UG | Ranitidine | none published | Import hold | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-26477586 | 01 Mar 2019 | UG | Adulterated Herbal products on the market | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-52040565 | 22 Jan 2019 | UG | Furosemide Injection BP Grand Pharmaceutical (China) Co., Ltd. | 180120 | Recall | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-40370607 | 22 Mar 2018 | UG | Rabicid-IV (Rabeprazole Injection IP) | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| Reference | Date | Country | Notice | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-UG-2025-31556372 | 02 Jul 2025 | UG | Retention of products on the register for the financial year 2025/2026 | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2025-45726480 | 08 May 2025 | UG | Regulation of promotion and advertisement of drug related information | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2025-39573016 | 18 Mar 2025 | UG | Clarification on fees payable for post approval amendments (variations) applications affecting multiple products | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-76423948 | 07 Oct 2024 | UG | Mandatory Post Shipment Circular | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-32874724 | 09 Sept 2024 | UG | Fast-Track assessment of variations (Amendments) and CTD dossier applications | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-14554633 | 13 Mar 2024 | UG | Circular on Importation of Healthcare Products for surgical / medical/ dental camps | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-93633050 | 08 Feb 2024 | UG | Circular No. 01-DPAR-2024_Submission of Vet Pharma Product Dossiers in CTD Format | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2023-24522908 | 05 May 2023 | UG | Circular on importation and distribution of Hypodermic Syringes and Needles | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2023-96986397 | 17 Feb 2023 | UG | Signposts for drug outlets | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2021-19688059 | 07 Oct 2021 | UG | Labelling requirements for surgical sutures | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2021-60049757 | 28 Jun 2021 | UG | National Drug Authority statement on conduct of Clinical Trials during the COVID-19 lockdown | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-58346661 | 23 Dec 2020 | UG | Emergency use of Remdesivir in the context of the Covid-19 Pandemic | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-24052569 | 04 Nov 2020 | UG | Pharmacovigilance requirements for Remdesivir products under emergency imp | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-55852107 | 19 Oct 2020 | UG | Requirement for a Pharmacovigilance system for licensed persons in Uganda | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-86995705 | 23 Sept 2020 | UG | Provisions for emergency importation of Remdesivir in the context of the COVID-19 Pandemic | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-63618631 | 27 Mar 2020 | UG | Circular on Importation, Exportation & sale of Chloroquine & Hydroxychloroquine | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-12969129 | 26 Mar 2020 | UG | Caution against stockpiling and irrational use of medicine | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-54174102 | 18 Dec 2019 | UG | Communication circular on Clinical Trial new format for CT certificates | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-91714961 | 30 Jan 2019 | UG | Clarification on Hydrochlorothiazide | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-95689534 | 14 Dec 2018 | UG | Disabling and potentially permanent side effects associated with quinolone and fluoroquinolone antibiotics | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-79023705 | 31 Aug 2018 | UG | Risk of crystalization of Mannitol 20% iv solution | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-44654198 | Aug 2018 | UG | Increased risk of non-melanoma skin cancer associated with HCTZ | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-57610380 | 23 May 2018 | UG | Gentamycin Injection | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-20732652 | 26 Mar 2018 | UG | Risk of drug interactions and side effects due to use of herbal remedies – Anticancer Treatment | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-83450762 | 27 Feb 2018 | UG | Certification of premises used to supply restricted drugs within institutions conducting clinical trials | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-54780957 | 15 Feb 2018 | UG | Risk of hypersensitivity reaction in infants and children following administration of Nevirapine | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2017-41564009 | 11 Dec 2017 | UG | Increased risk of otoxicity following concomitant administration of Gentamicin and Furosemide | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-30096701 | 01 Feb 2022 (uploaded) | UG | Implementation of the National Drug Policy and Authority (fees) Regulations 2022 | notice not read | Guidance | Unclassified | Tier 1 · Regulator-published |
Published by NDA but not an action against a product: draft regulations, import requirements, and safety signals about an active substance or a class of medicines rather than a particular pack. They are held to the same standard as everything else here — the source is archived, the verification tier is shown — and they are kept off the register because a batch search cannot answer a question about a whole drug class.
No action by another authority has been linked to this market.
Actions by other authorities that name this market on the notice, or that belong to a cross-border event this market also appears in. An absence here is an absence of recorded links, not a statement that no such product is on this market.